VC
TERN

Vivo Capital’s Terns Pharmaceuticals TERN Stock Holding History

Vivo Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.4M Sell
1,334,418
-4,012,510
-75% -$165M 5.85% 3
2025
Q4 		$216M Sell
5,346,928
-1,548,818
-22% -$35.8M 13.96% 1
2025
Q3 		$51.8M Hold
6,895,746
– – 4.17% 4
2025
Q2 		$25.7M Hold
6,895,746
– – 2.63% 7
2025
Q1 		$19M Hold
6,895,746
– – 2.52% 6
2024
Q4 		$38.2M Hold
6,895,746
– – 4.28% 4
2024
Q3 		$57.5M Buy
6,895,746
+712,754
+12% +$5.86M 4.76% 6
2024
Q2 		$42.1M Sell
6,182,992
-475,000
-7% -$2.88M 3.89% 8
2024
Q1 		$43.7M Hold
6,657,992
– – 3.43% 9
2023
Q4 		$43.2M Hold
6,657,992
– – 3.54% 8
2023
Q3 		$33.5M Hold
6,657,992
– – 3.67% 9
2023
Q2 		$58.3M Hold
6,657,992
– – 4.02% 5
2023
Q1 		$78.8M Hold
6,657,992
– – 5.47% 5
2022
Q4 		$67.8M Buy
6,657,992
+758,620
+13% +$5.05M 7.8% 2
2022
Q3 		$34.7M Buy
5,899,372
+3,224,239
+121% +$12M 3.84% 9
2022
Q2 		$6.63M Hold
2,675,133
– – 0.67% 33
2022
Q1 		$7.95M Hold
2,675,133
– – 0.55% 34
2021
Q4 		$18.9M Hold
2,675,133
– – 1.14% 22
2021
Q3 		$27.9M Hold
2,675,133
– – 1.25% 20
2021
Q2 		$32.8M Hold
2,675,133
– – 1.42% 19
2021
Q1 		$58.9M Buy
+2,675,133
New +$58.6M 2.07% 13

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vivo Capital's TERN Position: Q1 2026 in Review

Vivo Capital reduced its Terns Pharmaceuticals (TERN) stake by 75% in Q1 2026, selling an estimated $165M and leaving 1,334,418 shares worth $70.4M. The position accounts for 5.85% of the portfolio, ranked #3.

Vivo Capital first reported a position in TERN in Q1 2021 and has held it in 21 quarters since. The position peaked at $216M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Vivo Capital held 1,334,418 shares of Terns Pharmaceuticals worth $70.4M as of Q1 2026.
  • Vivo Capital sold 4,012,510 Terns Pharmaceuticals shares in Q1 2026, an estimated $165M.
  • Terns Pharmaceuticals made up 5.85% of Vivo Capital's portfolio in Q1 2026, its #3 holding.
  • Vivo Capital first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Vivo Capital's Terns Pharmaceuticals position peaked at $216M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.